Pharnext SA
PAR:ALPHA
Pharnext SA
Interest Expense
Pharnext SA
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharnext SA
PAR:ALPHA
|
Interest Expense
€1.2m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Interest Expense
€3.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
45%
|
|
|
Inventiva SA
PAR:IVA
|
Interest Expense
€16.7m
|
CAGR 3-Years
330%
|
CAGR 5-Years
301%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Interest Expense
$346k
|
CAGR 3-Years
46%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Interest Expense
€18.8m
|
CAGR 3-Years
123%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
Pharnext SA
Glance View
Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Issy-Les-Moulineaux, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.
See Also
What is Pharnext SA's Interest Expense?
Interest Expense
1.2m
EUR
Based on the financial report for Jun 30, 2023, Pharnext SA's Interest Expense amounts to 1.2m EUR.
What is Pharnext SA's Interest Expense growth rate?
Interest Expense CAGR 5Y
-5%
Over the last year, the Interest Expense growth was -31%. The average annual Interest Expense growth rates for Pharnext SA have been -18% over the past three years , -5% over the past five years .
